Beam Therapeutics

Curious how base editing works? Check out our animation and learn how the #BeamTeam is tackling diseases one letter at a time! #DaretoBeam

John Evans, chief executive officer of Beam, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 1:30 p.m. PT in San Francisco. A live webcast will be available in the investor section of the company's website https://lnkd.in/ej4z5M_S #DaretoBeam #BeamTeam #JPM

The #BeamTeam is growing! Check out the roles we're hiring for across Quality, Clinical R&D, Clinical Operations, Corporate Communications, Finance, HR, and more! #DaretoBeam https://beamtx.com/jobs/

𝐀𝐒𝐇 𝟐𝟎𝟐𝟒: Beam Therapeutics' CEO John Evans on the company's based editing sickle cell data, and preclinical data on a next generation product meant to broaden the potential patient population. He describes clinical data presented at #ASH24 for BEAM-101 and how he believes it stacks up against competition that is on the market. Plus, the ESCAPE program that is meant to avoid the use of Busulfan preconditioning, and how the company is progressing on other programs. Full video: https://lnkd.in/gVcjeKp3 BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | NYSE | Allucent | Klein Hersh

Today, new data for the Engineered Stem Cell Antibody Evasion (ESCAPE) conditioning platform were presented in an oral session at the 66th American Society of Hematology (ASH) Annual Meeting. The data demonstrated that conditioning with a monoclonal antibody successfully achieved long-term engraftment of base edited stem cells and induced robust levels of fetal hemoglobin. Read the full press release here: https://lnkd.in/eqzpKXRS #DaretoBeam #BeamTeam #ASH24

Today, new safety and efficacy data from the BEACON Phase 1/2 clinical trial of BEAM-101 in patients with sickle cell disease were featured today in the press program for the 66th American Society of Hematology (ASH) Annual Meeting and will be presented in an oral session on Sunday, Dec. 8, 2024, at 10 a.m. PT. Read the full update here: https://lnkd.in/egH4VkmY #DaretoBeam #BeamTeam #ASH24   Beam will host a live and webcast investor event on Dec. 8 at 8:00 p.m. PT to review the key presentations from this year’s ASH meeting. The event will be webcast live and can be accessed under “Events & Presentations” in the Investors section Beam’s website.

Today, Beam announced the appointment of Sravan K. Emany as chief financial officer (CFO), effective December 19, 2024. Mr. Emany brings to Beam a breadth of global operational, commercial and financial experience with multinational public corporations and financial institutions. He most recently served as CFO and chief operating officer at Ironwood Pharmaceuticals, Inc. Welcome to the #BeamTeam, Sravan! Read the press release here: https://lnkd.in/ezPzYnGb #DaretoBeam

Today, Beam announced the appointment of Chirfi Guindo, chief marketing officer of Human Health at Merck & Co., Inc., to its board of directors. Mr. Guindo is a seasoned executive in the pharmaceutical industry and has been a key leader at Merck for more than 25 years, where he held senior executive roles spanning global strategy, commercial operations and leadership in healthcare solutions. Welcome to the #BeamTeam, Chirfi! Read the press release here: https://lnkd.in/d4n_TjZw #DaretoBeam

Today, we are sharing Dan's story in honor of the conclusion of Alpha-1 Awareness Month and to bring continued awareness to Alpha-1 throughout the year #Alpha1AwarenessMonth #DaretoBeam

The #BeamTeam's Brian Riley will be speaking at the Executive Platforms Biomanufacturing World Summit this November in San Diego. Brian will join other global biomanufacturing leaders in discussions around critical topics facing our industry. Learn more about these conversations here https://lnkd.in/e-DyS_QA #BMWS24 #BioManufacturingSummit